To this end, we selected several IDH1/2-WT and -mutant cholangiocarcinoma, fibrosarcoma and chondrosarcoma cell lines, and we first tested monotherapy PARP and ATR inhibitor sensitivity in order to identify the appropriate dose ranges for the combination drug studies (Supplementary Figure S1A and B). This evidence concerns the gene IDH1 and fibrosarcoma.